PROG Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2022 @ 00:00):

Stats
Today's Volume	2.78M
Average Volume	6.37M
Market Cap	8.18M
EPS	$-0.0640 ( 2022-05-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.257
ATR14	$0.131 (14.81%)

Insider Trading

Date	Person	Action	Amount	type
2022-04-15	Desparbes Eric	Buy	231 693	Common Stock
2022-04-15	Neumann Clarke	Buy	184 843	Common Stock

INSIDER POWER
0.00
Last 2 transactions
Buy: 416 536 \| Sell: 0

Volume Correlation

Long: 0.62 (weak)

Short: 0.84 (strong)

Signal:(38.248) Same movement expected

Progenity, Inc. Correlation

10 Most Positive Correlations
ENNV	0.946
TVACW	0.926
SRNGW	0.916
HJLIW	0.904
AZRX	0.902
LSAQ	0.887
XPDI	0.88
OBLN	0.878
SRNG	0.867
TCDA	0.856

10 Most Negative Correlations
FTIV	-0.909
SCOB	-0.881
MSAC	-0.874
BCOR	-0.861
LGACU	-0.859
ITQ	-0.842
CTAQ	-0.831

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Progenity, Inc. Correlation - Currency/Commodity

-0.73
( moderate negative )

-0.67
( moderate negative )

0.51
( weak )

-0.71
( moderate negative )

0.44
( neutral )

Progenity, Inc. Financials

Annual	2023
Revenue:	$4 000.00
Gross Profit:	$-551 000 (-13 775.00 %)
EPS:	$-7.87

FY	2023
Revenue:	$4 000.00
Gross Profit:	$-551 000 (-13 775.00 %)
EPS:	$-7.87

FY	2022
Revenue:	$305 000
Gross Profit:	$-602 000 (-197.38 %)
EPS:	$-6.40

FY	2021
Revenue:	$1.25M
Gross Profit:	$1.25M (100.00 %)
EPS:	$-9.18

Financial Reports:

No articles found.

Progenity, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Progenity, Inc.

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.